(NASDAQ: VCYT) Veracyte's forecast annual revenue growth rate of 10.74% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.68%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.13%.
Veracyte's revenue in 2026 is $541,743,000.On average, 13 Wall Street analysts forecast VCYT's revenue for 2026 to be $47,725,578,024, with the lowest VCYT revenue forecast at $45,166,627,834, and the highest VCYT revenue forecast at $49,674,912,390. On average, 13 Wall Street analysts forecast VCYT's revenue for 2027 to be $53,369,311,946, with the lowest VCYT revenue forecast at $49,685,285,434, and the highest VCYT revenue forecast at $57,030,996,517.
In 2028, VCYT is forecast to generate $58,631,637,016 in revenue, with the lowest revenue forecast at $53,311,063,314 and the highest revenue forecast at $62,191,984,925.